<DOC>
	<DOCNO>NCT00529087</DOCNO>
	<brief_summary>The primary purpose protocol evaluate safety , efficacy , tolerability subcutaneous MOA-728 versus placebo subject chronic non-malignant pain Opioid-Induced Constipation ( OIC ) .</brief_summary>
	<brief_title>Study Evaluating Subcutaneous MOA-728 Treatment Opioid-Induced Constipation ( OIC ) Subjects With Chronic Non-Malignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Adult outpatient opioidinduced constipation chronic nonmalignant pain . Taking oral , transdermal , intravenous , subcutaneous opioids . Willingness discontinue prestudy laxative therapy use study permit rescue laxative . Exclusion Criteria History chronic constipation initiation opioid therapy . Other GI disorder know affect bowel transit . Women pregnant , breastfeeding , plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Opioid-Induced Constipation</keyword>
</DOC>